Journal article 1656 views
Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus
Diabetes Research and Clinical Practice, Volume: 94, Issue: 2, Pages: 199 - 206
Swansea University Authors:
Jeffrey Stephens , Sarah Prior
, Richard Bracken
, Gareth Dunseath
, Steve Luzio
Full text not available from this repository: check for access using links below.
DOI (Published version): 10.1016/j.diabres.2011.07.014
Abstract
To examine the effects of glibenclamide and repaglinide on glucose stimulated insulin release, incretins, oxidative stress and cell adhesion molecules in patients with type 2 diabetes suboptimally treated with metformin.A randomized clinical trial was performed recruiting 27 subjects (HbA1c between...
Published in: | Diabetes Research and Clinical Practice |
---|---|
Published: |
2011
|
Online Access: |
http://www.sciencedirect.com/science/article/pii/S0168822711003640 |
URI: | https://cronfa.swan.ac.uk/Record/cronfa10733 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
first_indexed |
2013-07-23T12:04:10Z |
---|---|
last_indexed |
2018-02-09T04:39:47Z |
id |
cronfa10733 |
recordtype |
SURis |
fullrecord |
<?xml version="1.0"?><rfc1807><datestamp>2014-12-05T15:05:08.5759284</datestamp><bib-version>v2</bib-version><id>10733</id><entry>2012-05-09</entry><title>Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus</title><swanseaauthors><author><sid>5219d126f97f8f884bdb622099bd41de</sid><ORCID>0000-0003-2228-086X</ORCID><firstname>Jeffrey</firstname><surname>Stephens</surname><name>Jeffrey Stephens</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>cdda101035997acfaa6fdf17097f52b2</sid><ORCID>0000-0001-8703-8092</ORCID><firstname>Sarah</firstname><surname>Prior</surname><name>Sarah Prior</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>f5da81cd18adfdedb2ccb845bddc12f7</sid><ORCID>0000-0002-6986-6449</ORCID><firstname>Richard</firstname><surname>Bracken</surname><name>Richard Bracken</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>fccbba9edcaee08a839a3c5cff8cbe19</sid><ORCID>0000-0001-6022-862X</ORCID><firstname>Gareth</firstname><surname>Dunseath</surname><name>Gareth Dunseath</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>01491e1cd582746a654fad9addf0de16</sid><ORCID>0000-0002-7206-6530</ORCID><firstname>Steve</firstname><surname>Luzio</surname><name>Steve Luzio</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2012-05-09</date><deptcode>BMS</deptcode><abstract>To examine the effects of glibenclamide and repaglinide on glucose stimulated insulin release, incretins, oxidative stress and cell adhesion molecules in patients with type 2 diabetes suboptimally treated with metformin.A randomized clinical trial was performed recruiting 27 subjects (HbA1c between 7.5 and 10.5%) free from cardiovascular and renal disease. Glucose, insulin, C-peptide, glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), total antioxidant status, F2-isoprostane, interleukin-6 and cell adhesion molecules were measured during an oral glucose load at baseline and after eight weeks of treatment. The areas under the curve were analysed at 45, 60 and 120 min (AUC45, AUC60, AUC120).Significant improvements in glucose were observed with repaglinide (HBA1c: −1.5%, fasting glucose: −2.8 mmol/L, 2-h glucose: −3.7 mmol/L, AUC120: −18.9%) and glibenclamide (−1.0%, −2.2 mmol/L, −2.5 mmol/L, −17.5%). Repaglinide was also associated with an increase in the AUC60 and AUC120 for insulin (+56%, +61%) and C-peptide (+41%, +36%). GLP-1, GIP, IL-6, ICAM-1 and E-selectin levels did not change in either group. No association was observed between GLP-1, GIP-1 and plasma markers of oxidative stress.Repaglinide is associated with improved postprandial glycaemic control via insulin and C-peptide release. We observed no direct effects of glibenclamide or repaglinide on plasma levels of GLP-1 or GIP. We observed no associations of GLP-1 and GIP with plasma markers of oxidative stress.</abstract><type>Journal Article</type><journal>Diabetes Research and Clinical Practice</journal><volume>94</volume><journalNumber>2</journalNumber><paginationStart>199</paginationStart><paginationEnd>206</paginationEnd><publisher/><issnPrint/><issnElectronic/><keywords>Glibenclamide; Repaglinide; GLP-1; GIP; Insulin; Oxidative stress; Diabetes</keywords><publishedDay>31</publishedDay><publishedMonth>12</publishedMonth><publishedYear>2011</publishedYear><publishedDate>2011-12-31</publishedDate><doi>10.1016/j.diabres.2011.07.014</doi><url>http://www.sciencedirect.com/science/article/pii/S0168822711003640</url><notes></notes><college>COLLEGE NANME</college><department>Biomedical Sciences</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>BMS</DepartmentCode><institution>Swansea University</institution><apcterm/><lastEdited>2014-12-05T15:05:08.5759284</lastEdited><Created>2012-05-09T11:17:26.4348781</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>Jeffrey</firstname><surname>Stephens</surname><orcid>0000-0003-2228-086X</orcid><order>1</order></author><author><firstname>T</firstname><surname>Bodvarsdottir</surname><order>2</order></author><author><firstname>K</firstname><surname>Wareham</surname><order>3</order></author><author><firstname>Sarah</firstname><surname>Prior</surname><orcid>0000-0001-8703-8092</orcid><order>4</order></author><author><firstname>R</firstname><surname>Bracken</surname><order>5</order></author><author><firstname>G</firstname><surname>Lowe</surname><order>6</order></author><author><firstname>A</firstname><surname>Rumley</surname><order>7</order></author><author><firstname>G</firstname><surname>Dunseath</surname><order>8</order></author><author><firstname>Steve</firstname><surname>Luzio</surname><order>9</order></author><author><firstname>C</firstname><surname>Deacon</surname><order>10</order></author><author><firstname>J</firstname><surname>Holst</surname><order>11</order></author><author><firstname>Steve</firstname><surname>Bain</surname><order>12</order></author><author><firstname>Richard</firstname><surname>Bracken</surname><orcid>0000-0002-6986-6449</orcid><order>13</order></author><author><firstname>Gareth</firstname><surname>Dunseath</surname><orcid>0000-0001-6022-862X</orcid><order>14</order></author><author><firstname>Steve</firstname><surname>Luzio</surname><orcid>0000-0002-7206-6530</orcid><order>15</order></author></authors><documents/><OutputDurs/></rfc1807> |
spelling |
2014-12-05T15:05:08.5759284 v2 10733 2012-05-09 Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus 5219d126f97f8f884bdb622099bd41de 0000-0003-2228-086X Jeffrey Stephens Jeffrey Stephens true false cdda101035997acfaa6fdf17097f52b2 0000-0001-8703-8092 Sarah Prior Sarah Prior true false f5da81cd18adfdedb2ccb845bddc12f7 0000-0002-6986-6449 Richard Bracken Richard Bracken true false fccbba9edcaee08a839a3c5cff8cbe19 0000-0001-6022-862X Gareth Dunseath Gareth Dunseath true false 01491e1cd582746a654fad9addf0de16 0000-0002-7206-6530 Steve Luzio Steve Luzio true false 2012-05-09 BMS To examine the effects of glibenclamide and repaglinide on glucose stimulated insulin release, incretins, oxidative stress and cell adhesion molecules in patients with type 2 diabetes suboptimally treated with metformin.A randomized clinical trial was performed recruiting 27 subjects (HbA1c between 7.5 and 10.5%) free from cardiovascular and renal disease. Glucose, insulin, C-peptide, glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), total antioxidant status, F2-isoprostane, interleukin-6 and cell adhesion molecules were measured during an oral glucose load at baseline and after eight weeks of treatment. The areas under the curve were analysed at 45, 60 and 120 min (AUC45, AUC60, AUC120).Significant improvements in glucose were observed with repaglinide (HBA1c: −1.5%, fasting glucose: −2.8 mmol/L, 2-h glucose: −3.7 mmol/L, AUC120: −18.9%) and glibenclamide (−1.0%, −2.2 mmol/L, −2.5 mmol/L, −17.5%). Repaglinide was also associated with an increase in the AUC60 and AUC120 for insulin (+56%, +61%) and C-peptide (+41%, +36%). GLP-1, GIP, IL-6, ICAM-1 and E-selectin levels did not change in either group. No association was observed between GLP-1, GIP-1 and plasma markers of oxidative stress.Repaglinide is associated with improved postprandial glycaemic control via insulin and C-peptide release. We observed no direct effects of glibenclamide or repaglinide on plasma levels of GLP-1 or GIP. We observed no associations of GLP-1 and GIP with plasma markers of oxidative stress. Journal Article Diabetes Research and Clinical Practice 94 2 199 206 Glibenclamide; Repaglinide; GLP-1; GIP; Insulin; Oxidative stress; Diabetes 31 12 2011 2011-12-31 10.1016/j.diabres.2011.07.014 http://www.sciencedirect.com/science/article/pii/S0168822711003640 COLLEGE NANME Biomedical Sciences COLLEGE CODE BMS Swansea University 2014-12-05T15:05:08.5759284 2012-05-09T11:17:26.4348781 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine Jeffrey Stephens 0000-0003-2228-086X 1 T Bodvarsdottir 2 K Wareham 3 Sarah Prior 0000-0001-8703-8092 4 R Bracken 5 G Lowe 6 A Rumley 7 G Dunseath 8 Steve Luzio 9 C Deacon 10 J Holst 11 Steve Bain 12 Richard Bracken 0000-0002-6986-6449 13 Gareth Dunseath 0000-0001-6022-862X 14 Steve Luzio 0000-0002-7206-6530 15 |
title |
Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus |
spellingShingle |
Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus Jeffrey Stephens Sarah Prior Richard Bracken Gareth Dunseath Steve Luzio |
title_short |
Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus |
title_full |
Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus |
title_fullStr |
Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus |
title_full_unstemmed |
Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus |
title_sort |
Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus |
author_id_str_mv |
5219d126f97f8f884bdb622099bd41de cdda101035997acfaa6fdf17097f52b2 f5da81cd18adfdedb2ccb845bddc12f7 fccbba9edcaee08a839a3c5cff8cbe19 01491e1cd582746a654fad9addf0de16 |
author_id_fullname_str_mv |
5219d126f97f8f884bdb622099bd41de_***_Jeffrey Stephens cdda101035997acfaa6fdf17097f52b2_***_Sarah Prior f5da81cd18adfdedb2ccb845bddc12f7_***_Richard Bracken fccbba9edcaee08a839a3c5cff8cbe19_***_Gareth Dunseath 01491e1cd582746a654fad9addf0de16_***_Steve Luzio |
author |
Jeffrey Stephens Sarah Prior Richard Bracken Gareth Dunseath Steve Luzio |
author2 |
Jeffrey Stephens T Bodvarsdottir K Wareham Sarah Prior R Bracken G Lowe A Rumley G Dunseath Steve Luzio C Deacon J Holst Steve Bain Richard Bracken Gareth Dunseath Steve Luzio |
format |
Journal article |
container_title |
Diabetes Research and Clinical Practice |
container_volume |
94 |
container_issue |
2 |
container_start_page |
199 |
publishDate |
2011 |
institution |
Swansea University |
doi_str_mv |
10.1016/j.diabres.2011.07.014 |
college_str |
Faculty of Medicine, Health and Life Sciences |
hierarchytype |
|
hierarchy_top_id |
facultyofmedicinehealthandlifesciences |
hierarchy_top_title |
Faculty of Medicine, Health and Life Sciences |
hierarchy_parent_id |
facultyofmedicinehealthandlifesciences |
hierarchy_parent_title |
Faculty of Medicine, Health and Life Sciences |
department_str |
Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine |
url |
http://www.sciencedirect.com/science/article/pii/S0168822711003640 |
document_store_str |
0 |
active_str |
0 |
description |
To examine the effects of glibenclamide and repaglinide on glucose stimulated insulin release, incretins, oxidative stress and cell adhesion molecules in patients with type 2 diabetes suboptimally treated with metformin.A randomized clinical trial was performed recruiting 27 subjects (HbA1c between 7.5 and 10.5%) free from cardiovascular and renal disease. Glucose, insulin, C-peptide, glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), total antioxidant status, F2-isoprostane, interleukin-6 and cell adhesion molecules were measured during an oral glucose load at baseline and after eight weeks of treatment. The areas under the curve were analysed at 45, 60 and 120 min (AUC45, AUC60, AUC120).Significant improvements in glucose were observed with repaglinide (HBA1c: −1.5%, fasting glucose: −2.8 mmol/L, 2-h glucose: −3.7 mmol/L, AUC120: −18.9%) and glibenclamide (−1.0%, −2.2 mmol/L, −2.5 mmol/L, −17.5%). Repaglinide was also associated with an increase in the AUC60 and AUC120 for insulin (+56%, +61%) and C-peptide (+41%, +36%). GLP-1, GIP, IL-6, ICAM-1 and E-selectin levels did not change in either group. No association was observed between GLP-1, GIP-1 and plasma markers of oxidative stress.Repaglinide is associated with improved postprandial glycaemic control via insulin and C-peptide release. We observed no direct effects of glibenclamide or repaglinide on plasma levels of GLP-1 or GIP. We observed no associations of GLP-1 and GIP with plasma markers of oxidative stress. |
published_date |
2011-12-31T03:12:12Z |
_version_ |
1763750059624628224 |
score |
11.021648 |